Preclinical scientific tests recommend that retatrutide may well impact obesity-linked most cancers progression. In the analyze led by Marathe et al., retatrutide-induced weight reduction diminished tumor engraftment, delayed tumor onset, and noticeably attenuated tumor development in pancreatic and lung cancer types, with larger tumor suppression